Vericel Corp (NASDAQ:VCEL)

11.70
Delayed Data
As of Jun 20
 -0.40 / -3.31%
Today’s Change
2.55
Today|||52-Week Range
14.75
+114.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$491.5M

Company Description

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Contact Information

Vericel Corp.
64 Sidney Street
Cambridge Massachusetts 02139
P:(617) 252-1999
Investor Relations:

Employees

Shareholders

Mutual fund holders8.49%
Individual stakeholders6.53%
Other institutional52.76%

Top Executives

Dominick C. ColangeloPresident, Chief Executive Officer & Director
Daniel R. OrlandoChief Operating Officer
Gerard J. MichelChief Financial & Accounting Officer
David ReckerChief Medical Officer
Jacquelyn Fahey SandellVice President & General Counsel